Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Microorganisms in Medicine and Therapeutics

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Gut microbiota-derived lysine phenylacetylation impairs mitochondrial function and is alleviated by SIRT3.

Cell metabolism·2026

Same author

Systematic Metabolic Engineering and Fermentation Optimization of <i>Yarrowia lipolytica</i> for High-Yield Production of Scutellarin.

Journal of agricultural and food chemistry·2026

Same author

Development of a Core-Shell-Encapsulated Biosensor for On-Site Detection of Trace Chlorpyrifos.

ACS sensors·2026

Same author

Actinobacteria TFDB: An integrated view of transcription factors in Actinobacteria.

Engineering microbiology·2026

Same author

Programmable DNA Origami-Based Protease Device for Precise and Direct Proteins Degradation.

Journal of the American Chemical Society·2026

Same author

Regulatory mechanism of cholesterol transport via LtmA in Mycobacterium smegmatis.

Scientific reports·2026

Search research articles

Related Experiment Video

Updated: Jun 5, 2025

Bioluminescent Bacterial Imaging In Vivo

Bioluminescent Bacterial Imaging In Vivo

Published on: November 4, 2012

Genetically engineered bacteria as inflammatory bowel disease therapeutics.

Zhen-Ping Zou¹, Xiao-Peng Zhang¹, Qian Zhang¹

¹Laboratory of Biosystems and Microanalysis, State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai, 200237, China.

Engineering Microbiology

|December 4, 2024

Summary

Genetically engineered bacteria offer a novel approach for diagnosing and treating inflammatory bowel disease (IBD). This review highlights advancements in using synthetic biology for IBD management and discusses challenges in clinical translation.

Keywords:

Bacterial therapeutics Genetically engineered bacteria Inflammatory bowel disease

More Related Videos

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice

Published on: December 16, 2021

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

Related Experiment Videos

Last Updated: Jun 5, 2025

Bioluminescent Bacterial Imaging In Vivo

Bioluminescent Bacterial Imaging In Vivo

Published on: November 4, 2012

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice

Published on: December 16, 2021

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

Area of Science:

Microbiology
Immunology
Synthetic Biology

Background:

Inflammatory bowel disease (IBD) is a chronic condition involving immune dysregulation and disruption of the gut microbiome.
Current IBD therapies manage symptoms but lack early diagnostic and intervention capabilities.

Purpose of the Study:

To review recent advancements in engineered bacteria for IBD detection and treatment.
To explore the potential of synthetic biology in developing novel IBD therapeutic strategies.

Main Methods:

Review of current literature on genetically engineered bacteria for IBD.
Analysis of bacterial modification for therapeutic molecule production and diagnostic functions.
Discussion of challenges in translating engineered bacteria into clinical applications.

Main Results:

Engineered bacteria can be designed for targeted IBD treatment and early detection.
Synthetic biology enables bacteria to produce therapeutic compounds or act as diagnostic sensors.
Significant challenges remain in the clinical translation of live bacterial therapeutics.

Conclusions:

Engineered bacteria represent a promising frontier for innovative IBD management.
Further research is needed to overcome delivery and safety hurdles for clinical use.
Synthetic biology holds potential to revolutionize IBD diagnosis and therapy.